Latest Breaking News On - Ulcerative colitis clinical - Page 2 : comparemela.com

DGAP-News: Immun . DGAP-News: Immunic, Inc. Announces Positive Top-Line Data From Investigator-Sponsored Phase 2 Proof-of-Concept Clinical Trial of IMU-838 in Primary Sclerosing Cholangitis vom 18.02.2021, 12:30 Uhr Bild: pixabay.com DGAP-News: Immunic, Inc. / Key word(s): Study results Immunic, Inc. Announces Positive Top-Line Data From Investigator-Sponsored Phase 2 Proof-of-Concept Clinical Trial of IMU-838 in Primary Sclerosing Cholangitis 18.02.2021 / 12:30 The issuer is solely responsible for the content of this announcement. Immunic, Inc. Announces Positive Top-Line Data From Investigator-Sponsored Phase 2 Proof-of-Concept Clinical Trial of IMU-838 in Primary Sclerosing Cholangitis - Statistically Significant Decrease in Serum Alkaline Phosphatase (ALP) Levels in the Per-Protocol Population After 24-Week IMU-838 Treatment, as Compared to Baseline -

United statesPaula schwartzEdna kaplanKeith lindorJohne eatonDaniel vittElizabeth careyJessica breuAndreas muehlerDepartment of internal medicineDivision of gastroenterologyNational institutes of healthRx communications groupDistribution servicesExchange commissionUs food drug administration